IVVD

Invivyd, Inc. · NASDAQ

Performance

+0.74%

1W

-14.68%

1M

+166.01%

3M

+118.82%

6M

+3.3%

YTD

+135.26%

1Y

Profile

Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease, as well as developing monoclonal antibody candidates, including VYD222 and VYD224, which provides neutralizing protection against SARS-CoV-2. It also has discovery stage candidates for the prevention of seasonal influenza. Invivyd, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Investment Analysis Report: IVVD

Overview:

IVVD is a company operating in the Health Technology sector, specifically in the Biotechnology industry. The company has a market capitalization of $462,482,832. In this report, we will conduct a comprehensive analysis of IVVD's financial statements over the past three years to evaluate its valuation, f...

See more ...

Technical Analysis of IVVD 2024-02-23

Overview:

In analyzing the technical indicators for IVVD stock over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions for potential ...

See more ...

Recent News & Updates